To illustrate how our technology-driven approach enables us to address fundamental biological questions and translate these insights into therapeutic discoveries, I will describe three newly developed high-throughput screening (HTS) technologies, ranging from the elucidation of the underlying molecular mechanisms of transcriptional regulation to single-cell proteomics and molecular glue discovery.

Bio: Dr. Heng Zhu is a full professor of pharmacology and molecular sciences and oncology at the Johns Hopkins School of Medicine. His research focuses on developing high-throughput screening technologies, including proteome arrays, VirD arrays, and a highly multiplexed DAPPL platform to investigate important basic science and translational questions.

Dr. Zhu is a pioneer proteomics technologist who co-invented protein microarray technology. Currently, his team is engaged in understanding the impacts of DNA epigenetic modifications on transcriptional regulation, characterization of function GWAS SNPs, and biomarker discovery.

Dr. Zhu received his undergraduate degree in chemistry from Peking University in Beijing, China. He earned his Ph.D. from Clemson University. He completed a postdoctoral fellowship in genetics at Yale University. Dr. Zhu joined the Johns Hopkins faculty in 2004.

Dr. Zhu's work has been recognized with numerous awards and honors, including two Chair's Awards from the Gordon Research Conference.